Inversago Pharma picks up $35m in Forbion-led Series B
Montreal-based Inversago Pharma, a peripheral CB1 blockade company, has raised US$35 million in Series B funding.
8 September 2020•1 min read
Montreal-based Inversago Pharma, a peripheral CB1 blockade company, has raised US$35 million in Series B funding.
BackingMinds raises €50m for Fund III, focused on Nordic start-ups
26 October 2026 · 3 mins read
Singapore VC plants flag in Ohio in search of US investors
26 October 2026 · 6 mins read
New AI threats are fueling VC investment in cybersecurity
22 October 2026 · 4 mins read
Inspired Capital holds quick close on $450m for Fund IV
20 October 2026 · 4 mins read
Inovia hits $200m in first close for sixth early-stage fund
19 October 2026 · 4 mins read
San Joaquin County to slow venture commitments
15 October 2026 · 2 mins read
DOWNLOAD: Fundraising holds steady in Q3
14 October 2026 · 2 mins read
